IL183825A0 - Crystalline forms of a factor xa inhibitor - Google Patents

Crystalline forms of a factor xa inhibitor

Info

Publication number
IL183825A0
IL183825A0 IL183825A IL18382507A IL183825A0 IL 183825 A0 IL183825 A0 IL 183825A0 IL 183825 A IL183825 A IL 183825A IL 18382507 A IL18382507 A IL 18382507A IL 183825 A0 IL183825 A0 IL 183825A0
Authority
IL
Israel
Prior art keywords
inhibitor
factor
crystalline forms
crystalline
forms
Prior art date
Application number
IL183825A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL183825A0 publication Critical patent/IL183825A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL183825A 2004-12-15 2007-06-10 Crystalline forms of a factor xa inhibitor IL183825A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63638704P 2004-12-15 2004-12-15
US73798505P 2005-11-18 2005-11-18
PCT/US2005/045158 WO2006065853A2 (en) 2004-12-15 2005-12-14 Crystalline forms of a factor xa inhibitor

Publications (1)

Publication Number Publication Date
IL183825A0 true IL183825A0 (en) 2007-09-20

Family

ID=36384503

Family Applications (1)

Application Number Title Priority Date Filing Date
IL183825A IL183825A0 (en) 2004-12-15 2007-06-10 Crystalline forms of a factor xa inhibitor

Country Status (15)

Country Link
US (2) US7371864B2 (enExample)
EP (1) EP1828187A2 (enExample)
JP (1) JP2008524228A (enExample)
KR (1) KR20070087606A (enExample)
AR (1) AR053990A1 (enExample)
AU (1) AU2005317158A1 (enExample)
BR (1) BRPI0519331A2 (enExample)
CA (1) CA2589886A1 (enExample)
IL (1) IL183825A0 (enExample)
MX (1) MX2007006919A (enExample)
NO (1) NO20072666L (enExample)
PE (1) PE20060739A1 (enExample)
RU (1) RU2007126770A (enExample)
TW (1) TW200634011A (enExample)
WO (1) WO2006065853A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2636757B1 (en) 2008-05-27 2016-11-23 Dako Denmark A/S Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers
US9303287B2 (en) 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
EP3252173A1 (en) 2011-10-21 2017-12-06 Dako Denmark A/S Hybridization compositions and methods
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
GEP20074098B (en) * 2001-09-21 2007-05-10 Bristol Myers Squibb Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
US7388096B2 (en) 2004-09-28 2008-06-17 Bristol-Myers Squibb Company Crystalline forms of a factor Xa inhibitor
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

Also Published As

Publication number Publication date
BRPI0519331A2 (pt) 2009-01-20
US7371864B2 (en) 2008-05-13
JP2008524228A (ja) 2008-07-10
TW200634011A (en) 2006-10-01
US20060148846A1 (en) 2006-07-06
WO2006065853A3 (en) 2006-08-24
NO20072666L (no) 2007-09-07
KR20070087606A (ko) 2007-08-28
AR053990A1 (es) 2007-05-30
MX2007006919A (es) 2007-06-26
WO2006065853A2 (en) 2006-06-22
CA2589886A1 (en) 2006-06-22
EP1828187A2 (en) 2007-09-05
PE20060739A1 (es) 2006-08-16
AU2005317158A1 (en) 2006-06-22
RU2007126770A (ru) 2009-01-27
US20080188517A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
IL178807A0 (en) Factor xa inhibitors
IL180853A0 (en) Crystalline form of a biphenyl compound
IL186023A0 (en) Crystalline form of a quinolinone-carboxamide compound
IL185471A0 (en) Crystalline forms of a biphenyl compound
PL3281939T3 (pl) Kombinacja zawierająca trwały kryształ związku 4-oksochinolinowego
IL177253A0 (en) PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS
IL223681A0 (en) Hydroxybenzoate salts of metanicotine compounds
IL169323A0 (en) Pyrazole-derivatives as factor xa inhibitors
GB0504995D0 (en) Use of a compound
EP1807082A4 (en) INHIBITOR COMPOUNDS OF XA FACTORS
IL177470A0 (en) BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS
IL183825A0 (en) Crystalline forms of a factor xa inhibitor
IL187981A0 (en) Crystalline forms of a pyrrolotriazine compound
IL188851A0 (en) Salts and polymorphs of a vegf-r inhibitor
GB0524017D0 (en) Generation of a categorisation scheme
ZA200508151B (en) Benzimidazole-derivatives as factor Xa inhibitors
ZA200704263B (en) Crystalline forms of a factor Xa inhibitor
HK1106768A (en) Crystalline forms of a factor xa inhibitor
IL185208A0 (en) Crystalline forms of a known pyrrolidine factor xa inhibitor
ZA200703622B (en) Novel use of α-sympathomlmetics having a 2-imidazoline structure
ZA200706428B (en) Crystalline ACAT inhibitor
GB0421867D0 (en) Factor Xa inhibitors
IL177451A0 (en) Crystalline forms of a pharmaceutical compound
GB0522829D0 (en) Use of a compound
HK1109900A (en) Factor xa inhibitors